Compare ZDGE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZDGE | BOLD |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 36.5M |
| IPO Year | 2016 | 2024 |
| Metric | ZDGE | BOLD |
|---|---|---|
| Price | $3.21 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 66.2K | ★ 366.0K |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $0.96 |
| 52 Week High | $4.70 | $1.72 |
| Indicator | ZDGE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 61.19 |
| Support Level | $2.90 | $1.12 |
| Resistance Level | $3.19 | $1.55 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 36.00 | 52.17 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.